Form 4 for VRTX Vertex Pharmaceuticals
Accepted 2026-02-19 00:00:00 ET · period of report 2026-02-17 · accession 0000875320-26-000088 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| M | 2026-02-19 | 2026-02-17+ | VRTX | Bunnage Mark E. | EVP, CSO | S - Sale | $484.31 | -3,619 | 9,668 | -27% | -$1.75M |
| 2026-02-19 | 2026-02-17 | VRTX | Bunnage Mark E. | EVP, CSO | F - Tax | $483.75 | -1,110 | 12.1K | -8% | -$537.0K | |
| 2026-02-19 | 2026-02-17 | VRTX | Bunnage Mark E. | EVP, CSO | A - Grant | $0.00 | +2,584 | 13.2K | +24% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-02-18 | S | D | 1,182 | $473.68 | 8,486 | D | — | — | |
| 2 | Common | Common Stock | 2026-02-17 | S | D | 2,437 | $489.46 | 9,668 | D | — | — | |
| 3 | Common | Common Stock | 2026-02-17 | F | D | 1,110 | $483.75 | 12,105 | D | — | — | |
| 4 | Common | Common Stock | 2026-02-17 | A | A | 2,584 | $0.00 | 13,215 | D | — | — | (F1) Restricted stock unit award that vests in installments beginning on February 20, 2027. |